Ehave, Inc. remains a developmental stage company focused on digital mental health therapeutics and medical psychedelics data integration. The June 2025 acquisition of AI Headhunter, an AI-powered recruitment platform, marks a strategic pivot towards incorporating artificial intelligence capabilities, potentially broadening its technology scope. Despite these efforts, Ehave continues to grapple with sustained operating losses and severe liquidity constraints, raising substantial doubt about its ability to continue as a going concern beyond late 2026. Growth hinges on successful commercialization of its MegaTeam and Ninja Reflex products, alongside KetaDash’s ketamine infusion services platform.